HealthAbbott Reports 72.2% WGS Sensitivity for Two-Year Colorectal RecurrenceBy Naomi CalderOct 23, 2026, 11:58 PM UTC
HealthXBiotech Reports 12-Month Survival Threshold in TASKIN Cancer TrialBy Naomi CalderOct 19, 2026, 9:34 PM UTC
BusinesseFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal ChemistryBy Nasdaq OMXApr 26, 2018, 11:31 AM UTC
BusinesseFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 12:01 PM UTC
BusinessTreos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal CancerBy Nasdaq OMXApr 11, 2018, 12:15 PM UTC
BusinesseFFECTOR Announces Appointment of John W. Smither to its Board of DirectorsBy Nasdaq OMXMar 23, 2018, 6:00 PM UTC
BusinessClinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety ProfileBy Nasdaq OMXDec 11, 2017, 3:00 PM UTC
